Warning letter
Consolidated Chemical, Inc.: warning letter of Mar 23, 2004
FDA warning letter UCM146283 · Kansas City District Office
Key facts
| Reference number | UCM146283 |
|---|---|
| Company | Consolidated Chemical, Inc. |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Mar 23, 2004 |
| Posted date | Mar 23, 2004 |
| Issuing office | Kansas City District Office |
| Product type | Drugs |
| CFR sections cited | 211.165(f), 211.22, 211.194(a)(2), 211.84, 211.192, 211.67(a), 211.100(a), 211.113(a), 211.115(a), 211.166(a)(1) |
| Country | 3 |
| Inspection city | Saint Louis |
| Inspection ZIP | 63139-1114 |
| Inspection start date | Nov 17, 2003 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: